GlassScriptPhysician profile
Anjali Dhanda
NPI 1487996716
$1,024.93
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,008 · 2021: $17.17.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $178.38 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $174.56 | 2019 | |
| Janssen Pharmaceuticals, INC | $159.91 | 2019 | |
| Lundbeck LLC | $155.96 | 2019 | |
| Neurocrine Biosciences, INC. | $115.96 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $64.39 | 2019 | |
| Neos Therapeutics, LP | $36.00 | 2019 | |
| Shire North American Group INC | $35.52 | 2019 | |
| Arbor Pharmaceuticals, INC. | $34.87 | 2019 | |
| Bausch Health US, LLC | $30.43 | 2019 | |
| Avanir Pharmaceuticals, INC. | $21.78 | 2019 | |
| Abbvie INC. | $17.17 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anjali Dhanda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.